Fed. Circ. Won't Revive Genentech Lung Disease Patents
A Delaware federal judge rightly invalidated claims in a Roche unit's patents for a lung disease drug it paid $8 billion to acquire and properly held that a Novartis unit's generic...To view the full article, register now.
Already a subscriber? Click here to view full article